Small study aims to predict which breast cancer patients benefit from immunotherapy
NCT ID NCT05877859
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study is looking at how the immune system responds in people with early-stage triple negative breast cancer who receive standard chemotherapy plus the immunotherapy drug pembrolizumab before surgery. The goal is to see if certain immune markers in the blood or tumor tissue can predict whether the cancer will completely disappear after treatment. Only 10 participants will be enrolled, and the study does not test a new treatment but rather monitors responses to the current standard of care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab (a type of immunotherapy) given with standard chemotherapy
What this could lead to
If successful, this study could help doctors understand which patients with early-stage triple negative breast cancer are most likely to benefit from adding immunotherapy to chemotherapy before surgery.
What could go wrong
This is a very small pilot study with only 10 participants, so results may not apply to all patients. It is designed to gather information, not to prove a new treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER STAGE II are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emory University/Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact